AMGEN INC
AI Intelligence Briefcase
Synthesize all available public data, government contracts, patent filings, and funding rounds for AMGEN INC into a comprehensive strategic report.
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No recent patents found.
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that a jury in the United States District Court for the District of Delaware has returned a decisive verdict in the Company's favor in the patent infringement lawsuit against Amgen Inc., and Teneobio, Inc. (an Amgen subsidiary) (together, "Amgen").The verdict represents a complete victory f
Morgan Stanley Raises Amgen (AMGN) Price Target Following a Strong Start for Uplizna
With an annual dividend yield of 2.85%, Amgen Inc. (NASDAQ:AMGN) is included among the 12 High Yield Fortune 500 Stocks to Buy Now. Amgen Inc. (NASDAQ:AMGN) discovers, develops, manufactures, and delivers innovative medicines to fight some of the world’s toughest diseases. On June 10, Morgan Stanley analyst Terence Flynn raised the firm’s price target on […]
Here’s Why Amgen (AMGN) is Among the 7 Best Longevity Stocks to Buy Now
Amgen Inc. (NASDAQ:AMGN) is one of the 7 Best Longevity Stocks to Buy Now. On June 7, 2026, Amgen Inc. (NASDAQ:AMGN) announced new data at the American Diabetes Association 86th Scientific Sessions, including Phase 3 VESALIUS-CV subgroup results for Repatha in patients with high-risk diabetes and elevated LDL-C without prior heart attack or stroke. In […]
Goldman Sachs Trims Amgen (AMGN) Valuation but Sticks with Buy Rating
With a net profit margin of 20.96%, Amgen Inc. (NASDAQ:AMGN) is included among the 10 Most Profitable Dividend Stocks to Invest In Now. On June 5, Goldman Sachs lowered its price recommendation on Amgen Inc. (NASDAQ:AMGN) to $389 from $425. It reiterated a Buy rating on the stock. The firm adjusted its model after Amgen disclosed […]
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Amgen: Time For An Upgrade? Yes, I Think So
Amgen Inc. upgraded to cautious Buy: pipeline growth drivers, margin upside, and risk/reward near lows. Click for this AMGN stock update.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro